Several strategies have been used to mitigate the thrombocytopenia effect of BCL-XL inhibitors, such as the use of proteolysis targeting chimera (PROTAC), antibody-drug conjugates, or prodrugs targeting BCL-XL. This evidence concerns the gene BCL2L1 and Thrombocytopenia.